WESTLAKE, Texas--(BUSINESS WIRE)--MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), announced today that it has implemented a $20 maximum copay program for MOXATAG (amoxicillin extended-release) Tablets, 775 mg. The program is designed to keep a patient’s net out-of-pocket copay expense for a MOXATAG prescription at $20 or less. Today, MiddleBrook’s 300 field force representatives and district managers will begin supplying physicians with MOXATAG $20 maximum copay voucher cards to distribute to patients with MOXATAG prescriptions. Patients can redeem the voucher at the point-of-sale in conjunction with having a MOXATAG prescription filled.
